Brief: Intensity Therapeutics-Got Nasdaq Letter Due To Resignation Of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
19/04/2024 21:14
April 19 (Reuters) - Intensity Therapeutics Inc
INTS.O :
* INTENSITY THERAPEUTICS-GOT NASDAQ LETTER DUE TO
RESIGNATION OF
DANIEL DONOVAN FROM AUDIT COMMITTEE, CO NOT COMPLIANT WITH
NASDAQ LISTING RULE 5605
Source text for Eikon: [ID:https://bitly.ws/3imCJ]
Further company coverage: INTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intensity Therapeutics
See all newsIntensity Therapeutics Q2 net loss widens as R&D costs rise
Brief: Intensity Therapeutics Q2 Operating Income USD -3.084 Million
Intensity Therapeutics Q1 net loss narrows on lower R&D costs
Brief: Intensity Therapeutics Q1 Operating Income USD -2.526 Million
Brief: Intensity Therapeutics Inc - Increases ATM Offering Capacity To $60 Million On March 23, 2026 - SEC Filing